Compare Abbott Laboratories (ABT) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Campbell Soup Co. — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Campbell Soup Co. trades at $22.22 (market cap $6.83B). The key difference: Abbott Laboratories is far larger — about 24.4× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.81%). Which is the better fit depends on your goals.
| ABT | CPB | |
|---|---|---|
Market Cap | $166.94B | $6.83B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $34.03 |
52-Week Low | $82.57 | $20.00 |
Enterprise Value | $193.69B | $13.44B |
Dividend Yield | 2.63% | 6.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Campbell's (CPB) trades at $22.90, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock offers a 7% dividend yield but faces margin pressures with net income margin at 6.12%. Recent Q1 2026 earnings beat expectations at $0.50 EPS, though sales declined 4% year-over-year. The company is implementing cost cuts and portfolio simplification while expanding through partnerships like the new gluten-free soup with Banza.
CPB presents a value opportunity with low P/E of 11.11 and P/S of 0.68, but faces structural challenges including margin deterioration and competitive pressures. Analyst consensus leans cautious with 55% hold ratings and $19.75 price target below current levels. The high dividend yield provides income support, but investors should monitor execution of cost-saving initiatives and consumer response to new product innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
